SALT LAKE CITY, July 28, 2026
Co-Diagnostics, Inc. has announced two significant milestones that strengthen global preparedness against Ebola virus disease, with its Indian joint venture CoSara Diagnostics Pvt. Ltd. supplying SARAGENE® Bundibugyo Virus Test kits for analytical studies while the company simultaneously completing a successful proof-of-concept study for the first blood-borne Ebola assay designed for the Co-Dx PCR Pro® point-of-care platform. The developments reinforce the company’s commitment to expanding rapid molecular diagnostics for emerging infectious diseases and improving outbreak preparedness through innovative PCR-based testing technologies. CoSara has provided 200 Bundibugyo virus test kits to a third-party laboratory following a request from the Centre for Cellular and Molecular Platforms (C-CAMP) under India’s InDx 2.0 National Diagnostics Catapult, an initiative supported by the India Department of Biotechnology to strengthen the nation’s pandemic preparedness capabilities. Together, these achievements demonstrate continued progress in enhancing diagnostic capacity for high-priority viral threats while expanding the capabilities of the Co-Dx PCR platform beyond traditional swab-based infectious disease testing.
CoSara Supports India’s Ebola Diagnostic Preparedness
The shipment of SARAGENE® Bundibugyo Virus Test kits marks an important collaboration between CoSara Diagnostics and India’s national diagnostics ecosystem. The analytical evaluation will assess the assay’s limit of detection, repeatability, and reproducibility, generating essential performance data that supports future diagnostic preparedness initiatives. The request originated from C-CAMP’s InDx 2.0 National Diagnostics Catapult, a government-supported program launched to improve India’s readiness for current and future infectious disease outbreaks by strengthening domestic diagnostic development capabilities. Built using Co-Diagnostics’ patented Co-Primers® technology, the centralized laboratory assay targets the Bundibugyo virus, one of the Ebola virus species responsible for outbreaks in East and Central Africa. In addition to the current assay, CoSara is actively developing a next-generation pan-Ebola molecular test capable of detecting multiple Ebola virus species, supporting earlier laboratory confirmation, faster outbreak response, and improved surveillance in regions vulnerable to future Ebola outbreaks.
Blood-Based Ebola Assay Expands PCR Pro Platform Capabilities
Alongside the CoSara announcement, Co-Diagnostics reported the successful completion of a proof-of-concept feasibility study evaluating an extraction-free Co-Primers® Ebola assay on the Co-Dx PCR Pro® instrument using diluted plasma samples. This achievement represents the first blood-borne assay successfully demonstrated on the company’s portable point-of-care PCR platform, significantly expanding the instrument’s future diagnostic potential. Previously focused primarily on swab-based infectious disease testing, the platform may now support a broader range of molecular diagnostics involving blood-derived specimens, opening opportunities for future menu expansion across infectious diseases and other clinical applications. According to Dwight Egan, Chief Executive Officer of Co-Diagnostics, the recent Ebola outbreak in Africa highlights the ongoing need for rapid diagnostic preparedness, and these parallel achievements demonstrate the company’s ability to respond quickly to emerging global public health challenges while advancing innovative molecular diagnostic technologies.
Advertisement
Molecular Diagnostics Strengthen Global Outbreak Response
The latest developments reinforce Co-Diagnostics’ long-term strategy of expanding its proprietary Co-Primers® molecular diagnostic platform to address emerging infectious diseases through highly specific nucleic acid detection technologies. Beyond Ebola virus testing, the company continues to develop assays for both centralized laboratory and future point-of-care applications, supporting earlier diagnosis, improved disease surveillance, and enhanced public health response capabilities worldwide. Although the Co-Dx PCR platform, including the PCR Pro®, PCR Home®, associated mobile applications, and related diagnostic assays, remains under regulatory review and is not yet commercially available, successful feasibility studies continue to demonstrate the platform’s versatility and future clinical potential. By combining innovative molecular assay design, expanding sample compatibility, and strategic collaborations with public health organizations, Co-Diagnostics is positioning itself to play an increasingly important role in global pandemic preparedness, molecular diagnostics innovation, and rapid response to emerging infectious disease threats while supporting healthcare systems with scalable, high-performance diagnostic technologies.
Source: Co-Diagnostics press release
